To date, anti-VEGF intravitreal injection is the most commonly performed ophthalmic procedure for the treatment of different retinal diseases such as neovascular AMD, diabetic retinopathy, retinal vein occlusion and secondary neovascularization in tumoral or inflammatory diseases [4,5,6,7,8]. The gene discussed is VEGFA; the disease is Abnormal retinal morphology.